Viridian Therapeutics (VRDN)
(Delayed Data from NSDQ)
$17.44 USD
+0.58 (3.44%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $17.42 -0.02 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VRDN 17.44 +0.58(3.44%)
Will VRDN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRDN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRDN
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates
Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last?
VRDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
MannKind (MNKD) Matches Q3 Earnings Estimates
Other News for VRDN
Viridian Therapeutics Announces Inducement Grants for New Employees | VRDN stock news
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VRDN ...
Viridian partners with Japanese firm for Veligrotug and VRDN-003
Viridian Therapeutics (VRDN) Partners with Kissei for Japanese Market Expansion
Viridian enters veligrotug, VRDN-003 collaboration and license pact with Kissei